Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire delivers record annual results in 2015

Shire delivers record annual results in 2015

18th February 2016

Shire has announced its financial results for 2015, during which it delivered a record annual revenue total of $6.42 billion (4.49 billion pounds).

This represents a year-on-year increase of seven percent, while its non-GAAP diluted earnings per share increase by ten percent to $11.68. The company expressed satisfaction with what was described as a transformative year for Shire.

During the last 12 months, sales of key products such as Vyvanse, Cinryze, Firazyr, Lialda/Mezavent and Natpara all grew, while it was able to significantly progress its pipeline, with 14 programmes either in phase III testing or deemed phase III-ready.

Meanwhile, it was able to grow its business with the acquisitions of NPS and Dyax, which will be followed soon by the planned merger with Baxalta.

The firm expects to generate double-digit topline growth and a seven to ten percent increase in non-GAAP diluted earnings per share in 2016.

Dr Flemming Ornskov, chief executive officer of Shire, said: "With the acquisition of Dyax and the planned combination with Baxalta, we are positioned for global leadership in rare diseases."ADNFCR-8000103-ID-801812856-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.